Investors Opening Eyes to Opportunity in Israel Cannabis, Including Exclusive CEO Video Interview Part #2
December 23rd, 2019
App, Exclusive, News, Top Story
There is no country on Earth that has a history steeped in cannabis research like that of Israel. Furthermore, there is no government that is more supportive of medical marijuana research than Israel. Yet, the small country has by and large gone overlooked for what it has to offer as an investment opportunity. That is until recently.
“[Israel has] broken down the barriers,” said Darryl Jones, CEO of Isracann Biosciences (CSE: IPOT) (OTC: ISCNF), in a Q&A session with CFN Media. “It’s flown under the radar for a while, but a lot of people are starting to come around and realize that Israel is a cannabis hub.”
Isracann, the first pure-play cannabis firm in Israel to list in Canada and U.S., is 100% focused on building out its fully-funded, 230,000 square-foot facility in the southern part of Israel. Isracann is working directly with Israeli Ministries and collaborating with a team of top lawyers and consultants to move the project expeditiously forward while staying onside with all regulatory processes. The company recently expanded in cultivation capacity through a new joint venture west of Be’er Sheva, Israel.
Birthplace of Cannabis Research
Dr. Raphael Mechoulam has rightfully earned the nickname the “Father of Marijuana Research.” More than 50 years ago, the Israeli organic chemist was the first person ever to isolate cannabidiol (CBD, a non-intoxicating compound in cannabis) and tetrahydrocannabinol (THC, the psychoactive component of cannabis). In the 1990’s, Dr. Mechoulam discovered that cannabinoids occur endogenously throughout the human body, making up the endocannabinoid system along with specific receptors.
Cannabinoids like CBD and THC, amongst more than 100 others, are compounds found in cannabis that act on cannabinoid receptors throughout the body, including the brain, nervous system, organs and tissue, to control a host of functions, such as pain management, the immune system, appetite and mood.
At 89 years of age, Dr. Mechoulam is still active in the cannabis space as a professor of Medicinal Chemistry at the Hebrew University of Jerusalem in Israel. His extensive body of work has earned him many awards, including a Lifetime Achievement Award at CannMed in 2016.
It is because of Dr. Mechoulam and his collaborators that scientists today are in the best position ever to understand regulation of the endocannabinoid system and what it can do for next-generation, cannabis-based medicines.
No Place Like It
Israel would not have its rich cannabis history if it weren’t for a supportive government. As discussed by Jones in the interview, Israel is the only country in the world where an organization can hold an independent research license and conduct studies on marijuana.
On top of friendly regulators, Mother Nature has blessed Israel with nearly perfect conditions for growing cannabis. Israel has 300+ days of sunshine each year, high UV rays and temperature and humidity that are ideal for growing the plant.
To that end, the country is highly regarded for its talent pool in agriculture and extensive infrastructure supportive of the industry.
This results in high-quality, low cost cannabis production.
Earlier this year, Israeli lawmakers passed legislation to allow for cannabis exports. That puts the country in elite company along with only the Netherlands and Canada as countries where cannabis exports are legal. It is expected that the framework will be in place to commence shipments in 2020.
According to Jones, the new laws will ultimately lead to Israeli technology and cannabis breaking into the European Union, getting into the hands of people that need and can benefit from it. In addition to serving the growing domestic market in Israel, Isracann has its sights set on Germany, the largest economy in the E.U. and one that has an emerging medical marijuana market.
Not Without Challenges
Jones has watched the cannabis industry in Canada unfold over the last couple decades, which brings experience to the up-and-coming market. To that point, he sees similarities between Israel and where Canada was 4-5 years ago. One of the biggest challenges for any emerging market is educating doctors and patients as to why cannabis can provide a therapeutic benefit.
Israelis are by no means completely unfamiliar with cannabis. In fact, the country has one of the highest per capita user rates in the world.
Currently, there are about 45,000 Israeli patients, with another 10,000 on a waiting list. The cannabis patient population is growing 10-15% annually, says Jones, which makes for a very attractive market opportunity immediately.
CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.